Dose-response relationship of MSCs as living Bio-drugs in HFrEF patients: a systematic review and meta-analysis of RCTs

Autor: Ziyad T. Ahmed, Maha Saad Zain Al-Abeden, Mohamed Ghaith Al Abdin, Mohamad Ayham Muqresh, Ghazi I. Al Jowf, Lars M. T. Eijssen, Khawaja Husnain Haider
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Stem Cell Research & Therapy, Vol 15, Iss 1, Pp 1-12 (2024)
Druh dokumentu: article
ISSN: 1757-6512
DOI: 10.1186/s13287-024-03713-4
Popis: Abstract Background Mesenchymal stem cells (MSCs) have emerged as living biodrugs for myocardial repair and regeneration. Recent randomized controlled trials (RCTs) have reported that MSC-based therapy is safe and effective in heart failure patients; however, its dose-response relationship has yet to be established. We aimed to determine the optimal MSC dose for treating HF patients with reduced ejection fraction (EF) (HFrEF). Methods The preferred reporting items for systematic reviews and meta-analyses (PRISMA) and Cochrane Handbook guidelines were followed. Four databases and registries, i.e., PubMed, EBSCO, clinicaltrials.gov, ICTRP, and other websites, were searched for RCTs. Eleven RCTs with 1098 participants (treatment group, n = 606; control group, n = 492) were selected based on our inclusion/exclusion criteria. Two independent assessors extracted the data and performed quality assessments. The data from all eligible studies were plotted for death, major adverse cardiac events (MACE), left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and 6-minute walk distance (6-MWD) as safety, efficacy, and performance parameters. For dose-escalation assessment, studies were categorized as low-dose (
Databáze: Directory of Open Access Journals
Nepřihlášeným uživatelům se plný text nezobrazuje